The countdown to International MPS Day has begun—learn more here

MPS II

Hunter Syndrome

What is MPS II?

MPS II is a mucopolysaccharide disease known as Hunter syndrome. It takes its name from Charles Hunter, the professor of medicine in Manitoba, Canada, who first described two brothers with the disease in 1917. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS II.

What Causes This Disease?

Mucopolysaccharides are chains of sugar molecules used to build connective tissues in the body.

“muco” refers to the thick jelly-like consistency of the molecules

“poly” means many

“saccharide” is a general term for a sugar molecule

The body constantly replaces used materials and breaks them down for disposal. MPS II patients are missing the enzyme iduronate sulfatase, which is essential to breaking down the mucopolysaccharides dermatan and heparan sulphate. These materials remain stored in the body’s cells, causing progressive damage. Babies may show little sign of the disease, but as cells sustain damage, symptoms start to appear.

To request more information about MPS and related LSD’s please contact us.

Frequently Asked Questions

This is a rare condition affecting 1 in 100,000 to 1 in 170,000 primarily males.

MPS II primarily occurs in boys, and girls may be carriers of the gene for MPS II. Although rare, MPS II has been diagnosed in girls. If the mother is a carrier, there is a 50 percent chance that any boy born will have the disease. The sisters and maternal aunts of a person with MPS II may be carriers of the disease and would also have a 50 percent chance of passing the syndrome to a son.

There is no cure, but treatments like enzyme replacement therapies can help make the disease more manageable.

Join the IMPSN Community

Opt-in today using your email and unlock a wealth of knowledge and support with just one click!